[Skip to Content]
[Skip to Content Landing]
Invited Commentary
May 2016

Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon CancerRequirements for Accurate Prognosis Assessment

Author Affiliations
  • 1Swiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Bern, Switzerland
  • 2Molecular Digestive Oncology Unit, Leuven University Hospital, Leuven, Belgium
JAMA Oncol. 2016;2(5):653-654. doi:10.1001/jamaoncol.2015.5226

Microsatellite instability (MSI) and mutations of BRAF and KRAS have been investigated as candidate biomarkers of “independent” prognostic value in patients with colorectal cancer for some time.1,2 Depending on tumor stage and treatment, their prognostic value seems to vary, but even in trials with similar populations and treatment the prognostic value is still controversial. Whether and how these 3 biomarkers are associated with outcome in patients with stage III colon cancer treated with combination leucovorin-calcium, fluorouracil, and oxaliplatin (FOLFOX)-based chemotherapy and how they influence each other are relevant research questions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×